Research programme: muscular dystrophy therapeutics - Prothelia/University of Nevada

Drug Profile

Research programme: muscular dystrophy therapeutics - Prothelia/University of Nevada

Alternative Names: Laminin-111; PRT-01; PRT-300; PRT-400; PRT-500

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Nevada Reno
  • Developer Prothelia; University of Nevada Reno
  • Class Proteins; Small molecules
  • Mechanism of Action Integrin modulators; Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy; Muscular dystrophies
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Duchenne muscular dystrophy; Limb girdle muscular dystrophies; Muscular dystrophies

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA
  • 28 Mar 2018 No recent reports of development identified for preclinical development in Limb-girdle-muscular-dystrophies in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Muscular-dystrophies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top